Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease

Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More